• Mashup Score: 6

    New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward…

    Tweet Tweets with this article
    • An MSK team led by @jaeparkmd found that giving a drug called anakinra patients undergoing #CARTcelltherapy reduced severe neurotoxicity from a rate of 28%–38% usually seen with standard anti-CD19 CAR T therapy to only 9.7%. Read more here: https://t.co/PyIGht61YW https://t.co/e7NA9WDEG8

  • Mashup Score: 0

    The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.The hold applies to IMMagine-1, a multicenter phase 2 trial evaluating the investigational therapy CART-ddBCMA (Arcellx Inc.).

    Tweet Tweets with this article
    • Two trials of investigational CAR-T therapies for cancer have been halted in six days after patient deaths. Is this cause for concern or an example of safety due diligence in action? https://t.co/cTSCSIaIyY #CARTCellTherapy #multiplemyeloma #leukemia #AML

  • Mashup Score: 0

    The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.The hold applies to IMMagine-1, a multicenter phase 2 trial evaluating the investigational therapy CART-ddBCMA (Arcellx Inc.).

    Tweet Tweets with this article
    • The @US_FDA placed a hold on IMMagine-1, a phase 2 trial evaluating CART-ddBCMA, after the death of a patient treated with the investigational CAR T-cell therapy. https://t.co/cTSCSIaIyY #CARTCellTherapy #CART #multiplemyeloma

  • Mashup Score: 1

    CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.Treatment with the chimeric antigen receptor T-cell therapy reduced the risk for death by 27.4% compared with standard care, updated

    Tweet Tweets with this article
    • Second-line axicabtagene ciloleucel extended OS in relapsed or refractory large B-cell lymphoma. @GoHealio spoke with @DrJasonWestin of @MDAndersonNews to learn more. #ASCO23 #ZUMA7 #CART #CARTCellTherapy @KitePharma #axicel https://t.co/V55E2ACZWK